Aprobación 12 de Julio, 2012 |
Primera edición 20 de Julio, 2012 |
Segunda edición, ampliada y corregida 7 de Junio, 2021 |
|
Artículo completo
IDENTIFICACION DE LA TRANSMISION DEL VIRUS DE LA HEPATITIS C MEDIANTE EL USO DE UNA PLATAFORMA DE SECUENCIACION DE SEGUNDA GENERACION
ACMD. The primary prevention of Hepatitis C among injecting drug users. 2009. Beerenwinkel N, Zagordi O. Ultra-deep sequencing for the analysis of viral populations. Current Opinion in Virology 1:1-6, 2011. Boddiger D. Mexico eager to reduce demand for illicit drugs. Lancet 375:15-16, 2010. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. . MMWR Recomm Rep 47:1-39, 1998. Fischer GE, et al. Hepatitis C virus infections from unsafe injection practices at an endoscopy clinic in Las Vegas, Nevada, 2007-2008. Clin Infect Dis 51:267-273, 2010. Fonseca-Coronado S, et al. Specific detection of naturally occurring telaprevir and boceprevir (protease inhibitors) HCV resistant mutants among treatment naive infected individuals. J Clin Microbiol, 2011. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 49:561-573, 2009. Katoh K, Toh H. Recent developments in the MAFFT multiple sequence alignment program. Brief Bioinform 9:286-298, 2008. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 17:107-115, 2011. Martin NK, et al. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. Journal of Hepatology 54:1137-1144, 2011. Martin NK, Vickerman P, Hickman M. Mathematical modelling of hepatitis C treatment for injecting drug users. J Theor Biol 274:58-66, 2011. Mendez-Sanchez N, et al. Prevalence of hepatitis C infection in a population of asymptomatic people in a checkup unit in Mexico city. Dig Dis Sci 50:733-737, 2005. Nelson PK, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 378:571-583, 2011. Ramachandran S, Xia GL, Ganova-Raeva LM, Nainan OV, Khudyakov Y. End-point limiting-dilution real-time PCR assay for evaluation of hepatitis C virus quasispecies in serum: performance under optimal and suboptimal conditions. J Virol Methods 151:217-224, 2008. Rivera-Lopez MR, Zavala-Mendez C, Arenas-Esqueda A. Prevalence for seropositivity for HIV, hepatitis B and hepatitis C in blood donors. Gac Med Mex 140:657-660, 2004. Romero-Figueroa S, et al. Risk factors associated with hepatitis C virus infection in an urban population of the State of Mexico. Arch Virol, 2011. Sosa-Jurado F, et al. Hepatitis C virus infection in blood donors from the state of Puebla, Mexico. Virol J 7:18, 2010. Tamura K, et al. MEGA5: Molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol, 2011. Thompson ND, Perz JF, Moorman AC, Holmberg SD. Nonhospital health care-associated hepatitis B and C virus transmission: United States, 1998-2008. Ann Intern Med 150:33-39, 2009. |
|
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC. |